Skip to main content
. 2010 Nov 19;77(2):580–585. doi: 10.1128/AEM.01540-10

FIG. 4.

FIG. 4.

Structural analysis of ORF9-His-treated E. faecalis peptidoglycan. (A) Reversed-phase HPLC separation of ORF9-His-treated E. faecalis peptidoglycan. The numbers from 1 to 6 above the peaks indicate the isolated fractions. (B) Structures and molecular masses of the isolated fractions. *, peak numbers refer to the HPLC chromatograms; **, 1r, Ala-iGln-Lys(ɛ)-Ala-Ala; 2r, Ala-iGln-Lys[(ɛ)-Ala-Ala]-Ala-Ala; iGln, isoglutamine. (C) Determined structure of the ORF9-His-treated E. faecalis peptidoglycan.